Zimmer Biomet Director Accrues Phantom Stock Units via Deferred Compensation

Executive Summary

On October 2, 2026, Zimmer Biomet Holdings, Inc. ($ZBH) filed a Form 4 detailing an acquisition of phantom stock units by Director Sreelakshmi Kolli on September 30, 2026. The transaction represents standard director compensation under the company's deferred compensation plan.

Transaction Breakdown

• Insider: Sreelakshmi Kolli
• Role: Director
• Security: Phantom Stock Units (convertible 1-for-1 to Common Stock)
• Transaction Code: A (Award / Grant pursuant to Rule 16b-3(d))
• Volume: 173.901 units
• Conversion / Exercise Price: $89.85 per share
• Post-Transaction Holdings: 7,033.757 units (includes 17.252 units accrued via dividend reinvestment on July 31, 2026)

Strategic & Market Context

This acquisition reflects regular quarterly non-employee director compensation accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan. Phantom stock units settle in common stock within 60 days following the end of the director's board service. Given that this is an automated, compensation-related accrual rather than open-market buying, it holds minimal predictive signal for stock performance.